Rescue Hearing’s initial gene therapy product will target a genetic mutation known to cause progressive hearing loss which eventually leads to deafness.
Hearing loss affects over 466 million people worldwide, yet there are still no approved therapies to restore lost hearing. By harnessing the power of gene therapy, molecular imaging, and advanced diagnostics, we’re not just treating symptoms—we’re going straight to the source of hearing impairment.
Rescue Hearing Inc. is proud to have signed an exclusive worldwide license agreement with Myrtelle, a pioneer in gene therapy solutions. This partnership, launched in Q3 2022, is set to accelerate the development of next-generation hearing loss treatments.
RHI has assembled a team of visionary, internationally recognized physicians, scientists, and bioengineers who share a common passion for developing therapies for humans suffering from hearing loss. The team is developing therapeutic and diagnostic platforms that will address the most difficult hearing loss indications.
Our vision is to eliminate hearing loss as a chronic condition through groundbreaking advancements in gene therapy and medical innovation. We are committed to a future where genetic hearing loss is no longer a lifelong challenge but a treatable condition, giving millions the chance to experience the world of sound.
Our mission is to develop a portfolio of cutting-edge gene therapy products by collaborating with leading researchers and utilizing the latest biotechnology and diagnostics. Through innovation and expertise, we strive to create targeted treatments that restore hearing and transform lives worldwide.
We are pioneering the development of gene therapy solutions to address the root causes of progressive hearing loss. Our innovative pipeline includes two groundbreaking products—RHI100 and RHI200—designed to restore hearing and transform lives.
